Arthritis, Juvenile Rheumatoid Clinical Trial
Official title:
Identification of Genes Involved in Juvenile Idiopathic Arthritis by Wholel Exome Sequencing
Juvenile idiopathic arthritis (JIA) is considered to be a multifactorial disease caused by a combination of environmental factors and predisposing genetic factors. Twins studies found a strong heritability (strong genetic factors) but genetic studies such association studies of large cohorts of patient (GWAS or Genome Wide Association Study) have elucidated less than 20 % of the genetic basis of JIA. The vision of the genetics of multifactorial diseases has recently changed revealing a large clinical and genetic heterogeneity of these diseases. Indeed, the advent of next-generation sequencing identified non-multifactorial genetic hereditary disease related to mutations in genes having strong effect on the onset of the disease without real impact of environmental factors among the so called "multifactorial diseases" (Parkinson's, diabetes, osteoarthritis, Alzheimer's, hypertension ...)The investigators propose to study 30 families with several forms of JIA by next-generation sequencing. Identifying the genetic basis of JIA in these families will help to better understand the physiopathology of this disease and may help to the identification of novel therapeutic targets for other patients with JIA.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00807846 -
A Study To Evaluate The Effects Of Celecoxib (Celebrex®) Or Naproxen On Blood Pressure In Pediatric Subjects
|
Phase 4 | |
Completed |
NCT00279747 -
A One Year Double-blind Trial to Investigate the Efficacy and Safety of Meloxicam Oral Suspension in Juvenile Rheumatoid Arthritis (JRA/JIA)
|
Phase 3 | |
Completed |
NCT00652925 -
A Study to Evaluate the Efficacy and Safety of Celecoxib Suspension Compared to Naproxen Suspension in Patients With JRA
|
Phase 3 | |
Completed |
NCT02001844 -
Foot Orthoses (FOs) on Pain, Quality of Life and the Gait With Children Diagnosed With JIA
|
N/A | |
Completed |
NCT00731965 -
Safety and Efficacy of Measles, Mumps, Rubella Vaccination in Juvenile Idiopathic Arthritis
|
Phase 4 | |
Terminated |
NCT00868751 -
Single Patient Use of Tocilizumab in Systemic Onset Juvenile Idiopathic Arthritis
|
N/A | |
Terminated |
NCT00637780 -
Study To Determine The Pharmacokinetics Of Sulfasalazine In Children With Juvenile Idiopathic Arthritis
|
Phase 4 | |
Completed |
NCT00001614 -
The Safety and Efficacy of Chicken Type II Collagen on Uveitis Associated With Juvenile Rheumatoid Arthritis
|
Phase 1 | |
Completed |
NCT01412021 -
Special Investigation (All Case Survey) in Patients With Juvenile Idiopathic Arthritis
|
||
Enrolling by invitation |
NCT02377245 -
Juvenile Inflammatory Rheumatism (JIR) Cohorte
|
||
Completed |
NCT00426218 -
Safety, Efficacy and Pharmacokinetics of Subcutaneous ACZ885 in Patients With Systemic Juvenile Idiopathic Arthritis (SJIA)
|
Phase 1/Phase 2 | |
Completed |
NCT00034853 -
Meloxicam [Mobic] in Juvenile Rheumatoid Arthritis (JRA)
|
Phase 3 | |
Completed |
NCT06000566 -
Drug Compliance and Affecting Factors in Juvenile Idiopathic Arthritis
|
||
Terminated |
NCT00511329 -
Growth Hormone in Children With Juvenile Rheumatoid Arthritis (JRA) and With Crohn's Disease
|
Phase 2/Phase 3 | |
Terminated |
NCT00688545 -
Naturalistic Safety Registry Of Celecoxib (CELEBREX(R)) And NSAIDs In Juvenile Idiopathic Arthritis
|
||
Recruiting |
NCT00012506 -
The Safety and Efficacy of a Tumor Necrosis Factor Receptor Fusion Protein on Uveitis Associated With Juvenile Rheumatoid Arthritis
|
Phase 3 |